A clinical Response in Metastatic Castration-resistant Prostate Cancer
(mCRPC) Cases Treated with Supra-physiological Doses of Testosterone:
Bipolar Androgen Therapy
Senji
Hoshi1,
Vladimir
Bilim2,
Kiyotsugu
Hoshi1,
Takuya
Nakagawa3,
Sadanobu
Sato3,
Rie
Sakagami3,
Masato
Konno3,
Takashi
Kudo3,
Kenji
Numahata3,
Isoji
Sasagawa1
- Department of Urology Yamagata Tokushukai Hospital, Yamagata Japan.
- Department of Urology Kameda Daiichi Hospital, Niigata Japan.
- Department of Urology Yamagata Prefectural Central Hospital, Yamagata
Japan.
Senji Hoshi senjihoshi47@yahoo.co.jp
Vladimir Bilim vbilim@zoho.com
Kiyotsugu Hoshi kiyotsugu49@yahoo.co.jp
Takuya Nakagawa
ntakuya19930527@gmail.com
Sadanobu Sato
nobusada0517@gmail.com
Rie Sakagami
rier060209@gmail.com
Masato Konno m1zinedine19@gmail.com
Takashi Kudo
takashi0218kudo@yahoo.co.jp
Kenji Numahata numapyon.tom@gmail.com
Isoji Sasagawa
isoji.sasagawa@tokushukai.jp
Keywords: prostate cancer, metastatic castration-resistant prostate
cancer, testosterone injection, bipolar androgen therapy
Abbreviations:
T – testosterone
PCa – prostate cancer
CRPC – castration-resistant prostate cancer
mCRPC – metastatic castration-resistant prostate cancer
GS – Gleason score
iPSA – initial PSA
RRP – radical retropubic prostatectomy
ADT – androgen deprivation therapy
MAB – maximal androgen blockade
ARAT – androgen receptor-axis-targeted therapies
EBRT – external beam radiation therapy
QOL – quality of life
BMA – bone modifying agents
BAT – bipolar androgen therapy
AR – androgen receptor